Uniphar plc (FRA:0NR)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.04B +1.6% |
| Revenue (ttm) | 3.18B +10.1% |
| Net Income | 53.61M -19.1% |
| EPS | 0.21 -16.3% |
| Shares Out | n/a |
| PE Ratio | 19.44 |
| Forward PE | 14.57 |
| Dividend | 0.02 (0.51%) |
| Ex-Dividend Date | Sep 17, 2026 |
| Volume | n/a |
| Open | 3.990 |
| Previous Close | 4.025 |
| Day's Range | 3.985 - 3.990 |
| 52-Week Range | 3.235 - 4.930 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 8, 2026 |
About Uniphar
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with acces... [Read more]
Financial Performance
In 2025, Uniphar's revenue was 3.07 billion, an increase of 10.98% compared to the previous year's 2.77 billion. Earnings were 51.09 million, a decrease of -20.43%.
Financial StatementsNews
Uniphar posts 7.7pc rise in gross profit as all three divisions deliver growth
Uniphar Earnings Call Transcript: H1 2026
Strong H1 2026 results with 7.7% gross profit growth and 6.2% EBITDA growth, driven by robust organic performance across all divisions. Strategic investments in infrastructure and technology support long-term growth, with the group on track for EUR 200 million EBITDA by 2028.
Uniphar Quarterly report: H1 2026
Uniphar has published its H1 2026 quarterly earnings report on September 8, 2026.
Uniphar Slides: H1 2026
Uniphar has posted slides in relation to its H1 2026 quarterly earnings report, which was published on September 8, 2026.
Competition watchdog launches in-depth investigation into Uniphar’s acquisition of pharmacy software company TouchStore
Uniphar Earnings release: H1 2026
Uniphar released its H1 2026 earnings on July 28, 2026, summarizing the period's financial results.
Regulator says Uniphar must operate acquisition at ‘arm’s length’ pending competition review
The Competition and Consumer Protection Commission (CCPC) has imposed what it described as “interim measures” requiring Irish pharmaceuticals group Uniphar to operate its recently acquired TouchStore ...
Competition regulator ‘calls-in’ Uniphar acquisition for review
The Competition and Consumer Protection Commission (CCPC) has "called in” the acquisition of TouchStore Limited by healthcare services provider, Uniphar plc for review.
Healthcare group Uniphar reports revenue topping €3bn last year
Healthcare services group Uniphar has reportedwhat it called a strong set of full-year results, with earnings up sharply and revenue topping the €3bn mark.
Uniphar Earnings Call Transcript: H2 2025
Strong organic growth across all divisions drove EBITDA up 6% and EPS up 21% year-over-year, supported by strategic investments in infrastructure and technology. The group remains confident in achieving its EUR 200 million EBITDA target by 2028, with robust performance in pharma, medtech, and retail.
Uniphar Annual report: H2 2025
Uniphar has published its H2 2025 annual report on February 24, 2026.
Uniphar Slides: H2 2025
Uniphar has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 24, 2026.
Uniphar PLC (DUB:UPR) Q4 2025 Earnings Report Preview: What to Look For
Uniphar PLC (DUB:UPR) Q4 2025 Earnings Report Preview: What to Look For
Uniphar Earnings release: H2 2025
Uniphar released its H2 2025 earnings on January 27, 2026, summarizing the period's financial results.
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar Agreement
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar Agreement
Uniphar sees profits rise to 38m as growth accelerates
Operating profits at stock market-listed healthcare services firm Uniphar rose 5.6pc to 38.5m in the first half of the year.
Uniphar Earnings Call Transcript: H1 2025
Strong H1 2025 results with 8% organic gross profit growth and 21% EPS increase, driven by all divisions. Strategic investments in infrastructure and technology are expected to support medium-term EBITDA growth, with a €200m target by 2028.
Uniphar Quarterly report: H1 2025
Uniphar has published its H1 2025 quarterly earnings report on September 2, 2025.
Uniphar Slides: H1 2025
Uniphar has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 2, 2025.
Uniphar PLC (DUB:UPR) Q2 2025 Earnings Report Preview: What To Look For
Uniphar PLC (DUB:UPR) Q2 2025 Earnings Report Preview: What To Look For
The week ahead in business: Unemployment data, flash estimate on inflation and a host of trading updates
September is here and it is straight down to business with results and trading updates due from Kainos on Monday, Uniphar on Tuesday, Cairn Homes on Wednesday and Grafton Group.
Uniphar flags profit growth for first half of the year
Irish healthcare group Uniphar says the business achieved double-digit adjusted earnings per share growth in the first half of 2025, with 8pc organic gross profit growth and lower finance costs.
Uniphar agrees to undertakings pending injunction hearing over alleged breach of agreement
Dublin-based Thera seeks orders preventing Uniphar from blocking its trading account
Pharmacy brokerage Thera claims Uniphar breaching agreement in takeover bid
A pharmacy brokerage business has claimed in the High Court that pharma giant Uniphar is breaching an agreement in an attempted takeover bid and abusing its dominant position in the market.